Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 6
1999 6
2000 9
2001 4
2002 1
2003 6
2004 5
2005 12
2006 10
2007 12
2008 16
2009 18
2010 24
2011 20
2012 12
2013 13
2014 22
2015 43
2016 22
2017 22
2018 24
2019 21
2020 39
2021 34
2022 35
2023 27
2024 35
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

456 results

Results by year

Filters applied: . Clear all
Page 1
Psoriatic arthritis from a mechanistic perspective.
Schett G, Rahman P, Ritchlin C, McInnes IB, Elewaut D, Scher JU. Schett G, et al. Among authors: rahman p. Nat Rev Rheumatol. 2022 Jun;18(6):311-325. doi: 10.1038/s41584-022-00776-6. Epub 2022 May 5. Nat Rev Rheumatol. 2022. PMID: 35513599 Review.
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, Sheng S, Agarwal P, Zhou B, Zhuang Y, van der Heijde D, McInnes IB; DISCOVER-2 Study Group. Mease PJ, et al. Among authors: rahman p. Lancet. 2020 Apr 4;395(10230):1126-1136. doi: 10.1016/S0140-6736(20)30263-4. Epub 2020 Mar 13. Lancet. 2020. PMID: 32178766 Free article. Clinical Trial.
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S; FUTURE 2 Study Group. McInnes IB, et al. Among authors: rahman p. Lancet. 2015 Sep 19;386(9999):1137-46. doi: 10.1016/S0140-6736(15)61134-5. Epub 2015 Jun 28. Lancet. 2015. PMID: 26135703 Free article. Clinical Trial.
Traduction franco-canadienne de l’Assessment of Systematic Reviews Revised (AMSTAR 2) : validation transculturelle et fidélité interjuges.
Flowers H, Guitard P, King J, Fitzpatrick E, Bérubé D, Barette JA, Cardinal D, Cavallo S, O'Neil J, Charette M, Côté L, Gurgel-Juarez NC, Toupin-April K, Shallwani SM, Dorion M, Rahman P, Potvin-Gilbert M, Bartolini V, Lewis KB, Martini R, Lagacé J, Galipeau R, Ranger MC, Duquette-Laplante F, Perrier MF, Savard J, Paquet N, Tourigny J, Bérubé ME, Ba Haroon H, Duong P, Bigras J, Capistran J, Loew L. Flowers H, et al. Among authors: rahman p. Physiother Can. 2022 Jan 1;74(1):15-24. doi: 10.3138/ptc-2019-0104. Epub 2021 Mar 2. Physiother Can. 2022. PMID: 35185243 Free PMC article. French.
Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci.
International Genetics of Ankylosing Spondylitis Consortium (IGAS); Cortes A, Hadler J, Pointon JP, Robinson PC, Karaderi T, Leo P, Cremin K, Pryce K, Harris J, Lee S, Joo KB, Shim SC, Weisman M, Ward M, Zhou X, Garchon HJ, Chiocchia G, Nossent J, Lie BA, Førre Ø, Tuomilehto J, Laiho K, Jiang L, Liu Y, Wu X, Bradbury LA, Elewaut D, Burgos-Vargas R, Stebbings S, Appleton L, Farrah C, Lau J, Kenna TJ, Haroon N, Ferreira MA, Yang J, Mulero J, Fernandez-Sueiro JL, Gonzalez-Gay MA, Lopez-Larrea C, Deloukas P, Donnelly P; Australo-Anglo-American Spondyloarthritis Consortium (TASC); Groupe Française d'Etude Génétique des Spondylarthrites (GFEGS); Nord-Trøndelag Health Study (HUNT); Spondyloarthritis Research Consortium of Canada (SPARCC); Wellcome Trust Case Control Consortium 2 (WTCCC2); Bowness P, Gafney K, Gaston H, Gladman DD, Rahman P, Maksymowych WP, Xu H, Crusius JB, van der Horst-Bruinsma IE, Chou CT, Valle-Oñate R, Romero-Sánchez C, Hansen IM, Pimentel-Santos FM, Inman RD, Videm V, Martin J, Breban M, Reveille JD, Evans DM, Kim TH, Wordsworth BP, Brown MA. International Genetics of Ankylosing Spondylitis Consortium (IGAS), et al. Among authors: rahman p. Nat Genet. 2013 Jul;45(7):730-8. doi: 10.1038/ng.2667. Epub 2013 Jun 9. Nat Genet. 2013. PMID: 23749187 Free PMC article.
Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.
McInnes IB, Rahman P, Gottlieb AB, Hsia EC, Kollmeier AP, Xu XL, Jiang Y, Sheng S, Shawi M, Chakravarty SD, van der Heijde D, Mease PJ. McInnes IB, et al. Among authors: rahman p. Arthritis Rheumatol. 2022 Mar;74(3):475-485. doi: 10.1002/art.42010. Epub 2022 Feb 7. Arthritis Rheumatol. 2022. PMID: 34719872 Free PMC article. Clinical Trial.
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial.
Haberman RH, MacFarlane KA, Catron S, Samuels J, Blank RB, Toprover M, Uddin Z, Hu J, Castillo R, Gong C, Qian K, Piguet V, Tausk F, Yeung J, Neimann AL, Gulliver W, Thiele RG, Merola JF, Ogdie A, Rahman P, Chakravarty SD, Eder L, Ritchlin CT, Scher JU. Haberman RH, et al. Among authors: rahman p. BMJ Open. 2022 Dec 23;12(12):e063650. doi: 10.1136/bmjopen-2022-063650. BMJ Open. 2022. PMID: 36564123 Free PMC article.
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
Mease P, van der Heijde D, Landewé R, Mpofu S, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Meiser K, Readie A, Pricop L, Abrams K. Mease P, et al. Among authors: rahman p. Ann Rheum Dis. 2018 Jun;77(6):890-897. doi: 10.1136/annrheumdis-2017-212687. Epub 2018 Mar 17. Ann Rheum Dis. 2018. PMID: 29550766 Free PMC article. Clinical Trial.
Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study.
Mease PJ, Landewé R, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Readie A, Mpofu S, Delicha EM, Pricop L, van der Heijde D. Mease PJ, et al. Among authors: rahman p. RMD Open. 2021 Jul;7(2):e001600. doi: 10.1136/rmdopen-2021-001600. RMD Open. 2021. PMID: 34330846 Free PMC article. Clinical Trial.
456 results